Fulvestrant

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

The FDA recommends, but does not require, genetic testing prior to initiating treatment with Fulvestrant.

Excerpts from the Fulvestrant (Faslodex) drug label:

Fulvestrant "is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy."

"Certain types of breast cancer require estrogen, a female hormone, to grow." Fulvestrant "works by blocking the effect of estrogen on certain tumors. This may slow the growth of tumors that are stimulated by estrogen."

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Fulvestrant drug label PDF.